Multibillion-dollar cancer drug from Genentech loses 2nd FDA approval

San Francisco Business Journal

Nov 29, 2022

Five years ago, the FDA had granted a conditional "accelerated approval" of the drug in certain bladder cancer patients. But the company said a new study failed to hit marks that w…